Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CYTOSORBENTS CORPORATION reported revenue of $37M, up 4.1% year over year. Operating margin was -39.8% and net margin -22.1%, on a free-cash-flow margin of -33.8% with capital expenditure at 0.4% of revenue. Every figure is computed directly from CTSO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $37M | -39.8% | -22.1% |
| FY2024 | $36M | -46.2% | -58.2% |
| FY2023 | $31M | -102.8% | -94.1% |
| FY2022 | $35M | -90.9% | -94.6% |
| FY2021 | $43M | -52.7% | -56.9% |
How does CTSO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.